Generic Medicine Info
Indications and Dosage
Adult: 2.5-5 mg once daily in the morning. Max: 10 mg once daily.

Adult: 2.5-5 mg once daily, either alone or w/ other antihypertensives.
Hypersensitivity to sulfonamide-derived drugs, anuria.
Special Precautions
Patient w/ fluid and electrolyte disturbances, gout, DM, hypercholesterolaemia, parathyroid disease, history of allergy and bronchial asthma. May exacerbate SLE. Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Headache, cramping, weakness, orthostatic hypotension, pancreatitis, jaundice, sialadenitis, vomiting, diarrhoea, nausea, gastric irritation, constipation, anorexia, aplastic anaemia, haemolytic anaemia, agranulocytosis, leukopenia, thrombocytopenia, anaphylactic reactions, necrotising angiitis, Stevens-Johnson syndrome, resp distress, fever, purpura, urticaria, rash, photosensitivity, hyperglycemia, hyperuricemia, electrolyte imbalance, vertigo, dizziness, paraesthesia, muscle spasm, restlessness, transient blurred vision, xanthopsia, glycosuria.
Monitoring Parameters
Assess wt, input and output reports daily to determine fluid loss, BP, serum electrolytes, BUN, creatinine.
Symptoms: Electrolyte imbalance and signs of K deficiency (e.g. confusion, dizziness, muscular weakness, GI disturbances). Management: General supportive measures including replacement of fluids and electrolytes.
Drug Interactions
Increased risk of lithium toxicity. Hypokalaemia may develop during concomitant use of steroids or ACTH. Insulin requirement in DM patients may be altered. Decreased arterial responsiveness to norepinephrine. Increased responsiveness to tubocurarine. Potentiation of orthostatic hypotension by barbiturates or narcotics.
Food Interaction
Avoid alcohol as it may potentiate orthostatic hypotension.
Lab Interference
May interfere w/ tests for parathyroid function. May decrease serum protein-bound iodine (PBI) levels w/o signs of thyroid disturbance.
Description: Methyclothiazide inhibits Na reabsorption in the distal tubules causing increased excretion of Na and water, as well as K and hydrogen ions.
Onset: Approx 2 hr.
Duration: ≥24 hr.
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: 6 hr.
Distribution: Crosses the placenta and excreted in breast milk.
Excretion: Via urine as unchanged drug.
Store between 20-25°C. Protect from light and moisture.
MIMS Class
Anon. Methyclothiazide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/06/2014.

Buckingham R (ed). Methyclothiazide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/06/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Methyclothiazide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 04/06/2014.

Methyclothiazide tablet (Mylan Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/06/2014.

Wickersham RM. Methyclothiazide. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/06/2014.

Disclaimer: This information is independently developed by MIMS based on Methyclothiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in